{"id":"amg531","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the thrombopoietin receptor, which leads to increased platelet production. This can be beneficial for patients with thrombocytopenia or other platelet-related disorders.","oneSentence":"AMG531 is a thrombopoietin receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:08:40.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT07048249","phase":"EARLY_PHASE1","title":"Single Arm Romiplostim to Prevent CIT","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-01-26","conditions":"Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia","enrollment":26},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT07421167","phase":"PHASE2","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)","enrollment":164},{"nctId":"NCT03362177","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-30","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":165},{"nctId":"NCT07400341","phase":"PHASE2","title":"Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-31","conditions":"MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA)","enrollment":66},{"nctId":"NCT07400250","phase":"PHASE2","title":"Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-04-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":28},{"nctId":"NCT07321626","phase":"PHASE1","title":"Romiplostim N01 for Platelet Recovery After Haploidentical HSCT","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment","enrollment":130},{"nctId":"NCT03937154","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2020-02-26","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":145},{"nctId":"NCT07345000","phase":"PHASE3","title":"A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Treatment-naïve Severe Aplastic Anemia","enrollment":210},{"nctId":"NCT07278661","phase":"PHASE2","title":"Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-01-01","conditions":"Chirurgical Intervention, Thrombocytopaenia","enrollment":136},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT07206823","phase":"NA","title":"Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Primacy Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT07214025","phase":"","title":"Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-11-01","conditions":"Romiplostim N01, ITP","enrollment":100},{"nctId":"NCT07185893","phase":"NA","title":"A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jun wang","startDate":"2025-09","conditions":"Solid Tumor Malignancies, Cancer, CTIT-Chemotherapy Induced Thrombocytopenia, Thrombocytopenia","enrollment":106},{"nctId":"NCT04870346","phase":"","title":"Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-05-10","conditions":"Aplastic Anemia","enrollment":36},{"nctId":"NCT07162519","phase":"NA","title":"Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-09-20","conditions":"Cytotoxic Drugs, Romiplostim N01, Breast Cancer","enrollment":68},{"nctId":"NCT07128576","phase":"PHASE2","title":"Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-09-15","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT04673266","phase":"PHASE2","title":"Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-14","conditions":"Lymphoma Patients, Thrombocytopenia","enrollment":11},{"nctId":"NCT07063225","phase":"PHASE2","title":"Romiplostim N01 for Chemotherapy-induced Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08","conditions":"Chemotherapy-induced Thrombocytopenia, Romiplostim N01","enrollment":50},{"nctId":"NCT07043894","phase":"PHASE2","title":"Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-07-01","conditions":"Solid Tumors, Hematological Tumor, Children","enrollment":50},{"nctId":"NCT05325593","phase":"PHASE3","title":"Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2022-12-02","conditions":"Primary Immune Thrombocytopenia","enrollment":129},{"nctId":"NCT07003256","phase":"","title":"Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT","status":"ENROLLING_BY_INVITATION","sponsor":"Haikou Affiliated Hospital of Central South University Xiangya School of Medicine","startDate":"2024-09-01","conditions":"Thalassemia in Children","enrollment":30},{"nctId":"NCT06992128","phase":"PHASE2","title":"Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-05-22","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":129},{"nctId":"NCT04671901","phase":"PHASE2","title":"A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-10","conditions":"Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma","enrollment":2},{"nctId":"NCT06898983","phase":"PHASE2","title":"Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-03-31","conditions":"Cancer Treatment-induced Thrombocytopenia (CTIT)","enrollment":97},{"nctId":"NCT06686927","phase":"PHASE2","title":"Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-20","conditions":"Primary Immune Thrombocytopenia","enrollment":36},{"nctId":"NCT04638829","phase":"PHASE4","title":"Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim","status":"COMPLETED","sponsor":"Sobi, Inc.","startDate":"2021-03-15","conditions":"Immune Thrombocytopenia","enrollment":60},{"nctId":"NCT06759636","phase":"PHASE3","title":"FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-01-21","conditions":"CTIT: Cancer Therapy Induced Thrombocytopenia","enrollment":88},{"nctId":"NCT02052882","phase":"PHASE2","title":"Study of Romiplostim for Chemotherapy Induced Thrombocytopenia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-01-30","conditions":"Isolated Chemotherapy-induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06613880","phase":"PHASE2","title":"Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-10-24","conditions":"Aplastic Anemia, TPO Receptor Agonists","enrollment":48},{"nctId":"NCT06693791","phase":"PHASE2","title":"Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-12-01","conditions":"Platelet Recovery After Umbilical Cord Blood Transplantation","enrollment":34},{"nctId":"NCT06658834","phase":"PHASE2","title":"A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-01","conditions":"Primary Immune Thrombocytopenia","enrollment":129},{"nctId":"NCT06535685","phase":"PHASE4","title":"A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-02","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT04478227","phase":"EARLY_PHASE1","title":"TPO-Mimetic Use in Children for Hematopoietic Failure","status":"COMPLETED","sponsor":"Anjali Sharathkumar","startDate":"2020-08-18","conditions":"Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia","enrollment":15},{"nctId":"NCT06516484","phase":"PHASE4","title":"Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-07-30","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT02773290","phase":"PHASE2, PHASE3","title":"Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2016-05","conditions":"Aplastic Anemia","enrollment":46},{"nctId":"NCT06497036","phase":"PHASE3","title":"Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geropharm","startDate":"2023-04-04","conditions":"Drug Effect, Safety Issues, Immunogenicity","enrollment":160},{"nctId":"NCT00305435","phase":"PHASE2","title":"Safety Study of AMG 531 in Japanese Subjects With ITP","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-02","conditions":"Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":12},{"nctId":"NCT05492409","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2022-03-28","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":160},{"nctId":"NCT06440824","phase":"PHASE3","title":"A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2024-06-01","conditions":"CTIT-Chemotherapy Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06408324","phase":"","title":"Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe","status":"COMPLETED","sponsor":"European Research Consortium on ITP","startDate":"2022-11-24","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":275},{"nctId":"NCT02094417","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Korea Co., Ltd.","startDate":"2014-04-14","conditions":"Aplastic Anemia","enrollment":35},{"nctId":"NCT02868060","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Kyowa Kirin China Pharmaceutical Co., Ltd.","startDate":"2015-09","conditions":"Immune Thrombocytopenia (ITP)","enrollment":16},{"nctId":"NCT02868099","phase":"PHASE3","title":"Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Kyowa Kirin China Pharmaceutical Co., Ltd.","startDate":"2015-09","conditions":"Immune Thrombocytopenia","enrollment":203},{"nctId":"NCT05220878","phase":"PHASE3","title":"Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2021-09-09","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":160},{"nctId":"NCT04478123","phase":"PHASE2","title":"Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-07-14","conditions":"Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT06201663","phase":"PHASE3","title":"Romiplostim in Chemotherapy-Induced Thrombocytopenia","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-12-17","conditions":"Chemotherapy-induced Thrombocytopenia, Solid Malignancy","enrollment":30},{"nctId":"NCT06137105","phase":"","title":"Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2023-12-01","conditions":"ITP - Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT04427306","phase":"PHASE2","title":"Neoadjuvant T-VEC in High Risk Early Melanoma","status":"SUSPENDED","sponsor":"University of California, Davis","startDate":"2020-05-21","conditions":"Melanoma","enrollment":6},{"nctId":"NCT06009497","phase":"PHASE4","title":"Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Non Severe Aplastic Anemia","enrollment":44},{"nctId":"NCT02335268","phase":"PHASE2","title":"Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2015-05-21","conditions":"Myelodysplastic Syndromes","enrollment":77},{"nctId":"NCT00117143","phase":"PHASE1, PHASE2","title":"Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-12-02","conditions":"Thrombocytopenic Purpura","enrollment":16},{"nctId":"NCT04933942","phase":"PHASE2","title":"Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2022-09-13","conditions":"First Progression of MGMT Promoter-methylated Glioblastoma","enrollment":""},{"nctId":"NCT05861297","phase":"PHASE4","title":"Immune Thrombocytopenia Management in Adults","status":"UNKNOWN","sponsor":"Nahda University","startDate":"2020-05-05","conditions":"Immune Thrombocytopenia Purpura","enrollment":467},{"nctId":"NCT05652595","phase":"PHASE1","title":"Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2022-06-03","conditions":"Pharmacodynamics, Pharmacokinetics, Bioequivalence","enrollment":56},{"nctId":"NCT04915287","phase":"PHASE4","title":"Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia; Drugs, Chronic Liver Disease","enrollment":476},{"nctId":"NCT00508820","phase":"PHASE3","title":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-02-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenic Purpura","enrollment":407},{"nctId":"NCT00603642","phase":"PHASE3","title":"P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":34},{"nctId":"NCT00415532","phase":"PHASE3","title":"Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":234},{"nctId":"NCT00102336","phase":"PHASE3","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-04-07","conditions":"Thrombocytopenia, Idiopathic Thrombocytopenic Purpura","enrollment":62},{"nctId":"NCT00102323","phase":"PHASE3","title":"AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03-29","conditions":"Thrombocytopenia, Idiopathic Thrombocytopenic Purpura","enrollment":63},{"nctId":"NCT00614523","phase":"PHASE2","title":"Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-07-21","conditions":"MDS, Myelodysplastic Syndromes, Thrombocytopenia","enrollment":250},{"nctId":"NCT01143038","phase":"PHASE2","title":"Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-11-30","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":75},{"nctId":"NCT00907478","phase":"PHASE4","title":"Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-08-11","conditions":"Thrombocytopenia, Idiopathic Thrombocytopenic Purpura","enrollment":169},{"nctId":"NCT01516619","phase":"PHASE2","title":"Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"Non-Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT02279173","phase":"PHASE3","title":"Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-12-10","conditions":"Immune Thrombocytopenia","enrollment":203},{"nctId":"NCT04095936","phase":"PHASE2, PHASE3","title":"Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-12-03","conditions":"Aplastic Anemia","enrollment":24},{"nctId":"NCT03957694","phase":"PHASE2, PHASE3","title":"Study of AMG531(Romiplostim) in Patients With Aplastic Anemia","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2019-04-25","conditions":"Aplastic Anemia","enrollment":17},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT02046291","phase":"PHASE1","title":"Safety of Romiplostim (Nplate®) Following UCBT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-04-10","conditions":"Hematologic Malignancies","enrollment":21},{"nctId":"NCT03622931","phase":"PHASE2","title":"Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines","status":"TERMINATED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2014-02-01","conditions":"Ovarian Cancer","enrollment":21},{"nctId":"NCT04350164","phase":"","title":"Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.","status":"COMPLETED","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2012-04-01","conditions":"Wiskott-Aldrich Syndrome","enrollment":67},{"nctId":"NCT04588194","phase":"PHASE2","title":"Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"David Gomez Almaguer","startDate":"2020-11-01","conditions":"Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura","enrollment":12},{"nctId":"NCT02063763","phase":"","title":"TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2014-05-14","conditions":"Adult Patients, Immune Primary Thrombocytopenia, Splenectomy","enrollment":31},{"nctId":"NCT01971684","phase":"","title":"ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2013-08","conditions":"Immune Thrombocytopenia","enrollment":120},{"nctId":"NCT02760251","phase":"PHASE4","title":"Immunomodulation With Romiplostim in Young Adults With ITP","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-04","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT04371939","phase":"PHASE2","title":"Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-11-05","conditions":"Wiskott-Aldrich Syndrome","enrollment":30},{"nctId":"NCT04289207","phase":"PHASE2","title":"Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2020-03-01","conditions":"Immune Thrombocytopenia","enrollment":55},{"nctId":"NCT00440037","phase":"PHASE2, PHASE3","title":"Open Label Extension Study of AMG 531 in Japanese Subjects With ITP","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-11","conditions":"Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":44},{"nctId":"NCT01071954","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12-30","conditions":"Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP","enrollment":66},{"nctId":"NCT00111475","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-07-01","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":45},{"nctId":"NCT01443351","phase":"","title":"Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)","status":"WITHDRAWN","sponsor":"Zealand University Hospital","startDate":"2015-03","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":""},{"nctId":"NCT00902018","phase":"PHASE2","title":"Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2009-01","conditions":"Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT01980030","phase":"PHASE1, PHASE2","title":"Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11","conditions":"Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":24},{"nctId":"NCT00321711","phase":"PHASE2","title":"Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-10-01","conditions":"MDS, Myelodysplastic Syndromes, Thrombocytopenia","enrollment":69},{"nctId":"NCT01676961","phase":"PHASE2","title":"Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2013-01","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":5},{"nctId":"NCT03515447","phase":"","title":"Romiplostim in Thoracic Transplantation","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2014-05-01","conditions":"Thrombocytopenia","enrollment":30},{"nctId":"NCT02227576","phase":"PHASE2","title":"Prevention of Thrombocytopenia in Glioblastoma Patients","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2014-07-10","conditions":"Thrombocytopenia, Glioblastoma","enrollment":20},{"nctId":"NCT03343847","phase":"PHASE3","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2018-01-27","conditions":"Chemotherapy-induced Thrombocytopenia","enrollment":""},{"nctId":"NCT00472290","phase":"NA","title":"Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-04-01","conditions":"Hematology, MDS, Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT01236014","phase":"","title":"Indirect Comparison Between Eltrombopag & Romiplostim","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08","conditions":"Thrombocytopaenia","enrollment":1},{"nctId":"NCT01153919","phase":"PHASE2","title":"Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-06-30","conditions":"Hepatitis C Infection, Thrombocytopenia","enrollment":27},{"nctId":"NCT01444417","phase":"PHASE3","title":"Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":62},{"nctId":"NCT01974232","phase":"","title":"A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2012-01","conditions":"Immune Thrombocytopenia","enrollment":33},{"nctId":"NCT02085993","phase":"","title":"Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-07","conditions":"Immune Thrombocytopenic Purpura","enrollment":41},{"nctId":"NCT02338414","phase":"PHASE2","title":"An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-01","conditions":"Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT02090088","phase":"","title":"Nplate® Pregnancy Exposure Registry","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-05","conditions":"Birth Defect, Spontaneous Abortions, Low Birth Weight","enrollment":4},{"nctId":"NCT00515203","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-07","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":22},{"nctId":"NCT00147225","phase":"PHASE1, PHASE2","title":"AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08","conditions":"Solid Tumors, Advanced Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMG531","genericName":"AMG531","companyName":"Kyowa Kirin Korea Co., Ltd.","companyId":"kyowa-kirin-korea-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AMG531 is a thrombopoietin receptor agonist. Used for Thrombocytopenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}